Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin

Shiro Hinotsu; Hideyuki Akaza; Shigeo Isaka; Susumu Kagawa; Kenkichi Koiso; Toshihiko Kotake; Toyohei Machida; Yosuke Matsumura; Tadao Niijima; Koji Obata; Yasuo Ohashi; Hiroshi Ohe; Jun Shimazaki; Kazuya Tashiro

Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin

Shiro Hinotsu, Hideyuki Akaza, Shigeo Isaka, Susumu Kagawa, Kenkichi Koiso, Toshihiko Kotake, Toyohei Machida, Yosuke Matsumura, Tadao Niijima, Koji Obata, Yasuo Ohashi, Hiroshi Ohe, Jun Shimazaki, Kazuya Tashiro

University Hospital

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor(s). The primary endpoint was first recurrence after transurethral resection. Endoscopic examination as well as urinary cytology was performed in each case every three months. It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm. Toxicity was mainly restricted to bladder irritation in about 10% of patients in each instillation arm.

Original language	English
Pages (from-to)	73-80
Number of pages	8
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	29
Issue number	1
Publication status	Published - Jan 2002

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hinotsu, S., Akaza, H., Isaka, S., Kagawa, S., Koiso, K., Kotake, T., Machida, T., Matsumura, Y., Niijima, T., Obata, K., Ohashi, Y., Ohe, H., Shimazaki, J., & Tashiro, K. (2002). Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin. Gan to kagaku ryoho. Cancer & chemotherapy, 29(1), 73-80.

Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin. / Hinotsu, Shiro; Akaza, Hideyuki; Isaka, Shigeo et al.
In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 29, No. 1, 01.2002, p. 73-80.

Research output: Contribution to journal › Article › peer-review

Hinotsu, S, Akaza, H, Isaka, S, Kagawa, S, Koiso, K, Kotake, T, Machida, T, Matsumura, Y, Niijima, T, Obata, K, Ohashi, Y, Ohe, H, Shimazaki, J & Tashiro, K 2002, 'Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 29, no. 1, pp. 73-80.

@article{c2d95e988f46464e90f44294b8b22ed1,

title = "Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin",

abstract = "A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor(s). The primary endpoint was first recurrence after transurethral resection. Endoscopic examination as well as urinary cytology was performed in each case every three months. It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm. Toxicity was mainly restricted to bladder irritation in about 10% of patients in each instillation arm.",

author = "Shiro Hinotsu and Hideyuki Akaza and Shigeo Isaka and Susumu Kagawa and Kenkichi Koiso and Toshihiko Kotake and Toyohei Machida and Yosuke Matsumura and Tadao Niijima and Koji Obata and Yasuo Ohashi and Hiroshi Ohe and Jun Shimazaki and Kazuya Tashiro",

year = "2002",

month = jan,

language = "English",

volume = "29",

pages = "73--80",

journal = "Gan to kagaku ryoho. Cancer & chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "1",

}

TY - JOUR

T1 - Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

AU - Isaka, Shigeo

AU - Kagawa, Susumu

AU - Koiso, Kenkichi

AU - Kotake, Toshihiko

AU - Machida, Toyohei

AU - Matsumura, Yosuke

AU - Niijima, Tadao

AU - Obata, Koji

AU - Ohashi, Yasuo

AU - Ohe, Hiroshi

AU - Shimazaki, Jun

AU - Tashiro, Kazuya

PY - 2002/1

Y1 - 2002/1

N2 - A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor(s). The primary endpoint was first recurrence after transurethral resection. Endoscopic examination as well as urinary cytology was performed in each case every three months. It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm. Toxicity was mainly restricted to bladder irritation in about 10% of patients in each instillation arm.

AB - A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor(s). The primary endpoint was first recurrence after transurethral resection. Endoscopic examination as well as urinary cytology was performed in each case every three months. It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm. Toxicity was mainly restricted to bladder irritation in about 10% of patients in each instillation arm.

UR - http://www.scopus.com/inward/record.url?scp=0036363684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036363684&partnerID=8YFLogxK

M3 - Article

C2 - 11816482

AN - SCOPUS:0036363684

SN - 0385-0684

VL - 29

SP - 73

EP - 80

JO - Gan to kagaku ryoho. Cancer & chemotherapy

JF - Gan to kagaku ryoho. Cancer & chemotherapy

IS - 1

ER -

Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this